Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
SpringWorks has announced a research collaboration with the Dana-Farber Cancer Institute to advance its therapy development efforts for multiple myeloma and related diseases.
Laronde has managed to secure as much as $440 million from a Series B financing round to support as many as 100 Endless RNA (eRNA) products and drug programs over the next decade.
It was a busy week for clinical trial news. Here’s a look.
The combined company out of the Humacyte SPAC will be called Humacyte and is expected to trade shares of common stock and warrants on the Nasdaq Global Select Market.
Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
While the biotech market sees a high demand for the chief medical officer role, one Massachusetts oncology player has deemed the role completely unnecessary.
Pfizer Chief Executive Officer Albert Bourla tapped Aamir Malik to serve as the company’s chief business innovation officer.
Funds will be used to advance the clinical development of Cardior’s lead program, CDR132L, an oligonucleotide-based ncRNA inhibitor targeting micro-RNA-132.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.